Short Interest in Elekta AB (publ) (OTCMKTS:EKTAY) Expands By 200.0%

Elekta AB (publ) (OTCMKTS:EKTAY) was the target of a significant increase in short interest in the month of February. As of February 15th, there was short interest totalling 300 shares, an increase of 200.0% from the January 31st total of 100 shares. Based on an average trading volume of 6,300 shares, the days-to-cover ratio is currently 0.0 days.

Analyst Upgrades and Downgrades

Separately, Sanford C. Bernstein raised shares of Elekta AB (publ) from a “strong sell” rating to a “hold” rating in a research note on Wednesday, January 29th.

Elekta AB (publ) Trading Up 0.2 %

Shares of EKTAY traded up $0.01 during midday trading on Friday, hitting $5.43. The stock had a trading volume of 9,765 shares, compared to its average volume of 8,953. Elekta AB has a 1 year low of $5.25 and a 1 year high of $8.24. The firm has a market cap of $2.08 billion, a PE ratio of 21.72 and a beta of 1.22. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.05 and a quick ratio of 0.81. The stock’s 50 day moving average is $5.72 and its 200 day moving average is $6.07.

Elekta AB (publ) (OTCMKTS:EKTAY) last announced its earnings results on Friday, February 21st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Elekta AB (publ) had a net margin of 5.65% and a return on equity of 11.07%. The firm had revenue of $416.86 million during the quarter, compared to analysts’ expectations of $435.89 million. As a group, analysts forecast that Elekta AB will post 0.36 EPS for the current fiscal year.

Elekta AB (publ) Cuts Dividend

The business also recently declared a dividend, which will be paid on Thursday, March 27th. Investors of record on Friday, March 7th will be paid a $0.1072 dividend. The ex-dividend date is Friday, March 7th. Elekta AB (publ)’s dividend payout ratio is presently 40.00%.

About Elekta AB (publ)

Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity for real-time MR visualization; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for image guided radiation therapy; treatment and workflow management solutions; radiation and medical oncology; and other patient services.